Zuo Yawen, Li Tong, Yang Shilei, Chen Xuyang, Tao Xufeng, Dong Deshi, Liu Fang, Zhu Yanna
Department of Pharmacy, First Affiliated Hospital of Dalian Medical University, Dalian, China.
Department of Medical Oncology, The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China.
Front Pharmacol. 2025 Feb 17;15:1466877. doi: 10.3389/fphar.2024.1466877. eCollection 2024.
Renal cell carcinoma (RCC) is a common substantive tumor. According to incomplete statistics, RCC incidence accounts for approximately 90% of renal malignant tumors, and is the second most prevalent major malignant tumor in the genitourinary system, following bladder cancer. Only 10%-15% of chemotherapy regimens for metastatic renal cell carcinoma (mRCC) are effective, and mRCC has a high mortality. Drug transporters are proteins located on the cell membrane that are responsible for the absorption, distribution, and excretion of drugs. Lots of drug transporters are expressed in the kidneys. Changes in carrier function weaken balance, cause disease, or modify the effectiveness of drug treatment. The changes in expression of these transporters during cancer pathology results in multi-drug resistance to cancer chemotherapy. In the treatment of RCC, the study of drug transporters helps to optimize treatment regimens, improve therapeutic effects, and reduce drug side effects. In this review, we summarize advances in the role of renal drug transporters in the genesis, progression, and treatment of RCC.
肾细胞癌（RCC）是一种常见的实体肿瘤。据不完全统计，RCC的发病率约占肾恶性肿瘤的90%，是泌尿生殖系统中第二常见的主要恶性肿瘤，仅次于膀胱癌。转移性肾细胞癌（mRCC）的化疗方案只有10%-15%有效，且mRCC的死亡率很高。药物转运体是位于细胞膜上的蛋白质，负责药物的吸收、分布和排泄。许多药物转运体在肾脏中表达。载体功能的改变会削弱平衡、引发疾病或改变药物治疗的效果。这些转运体在癌症病理过程中的表达变化会导致对癌症化疗的多药耐药性。在RCC的治疗中，对药物转运体的研究有助于优化治疗方案、提高治疗效果并减少药物副作用。在本综述中，我们总结了肾脏药物转运体在RCC发生、发展和治疗中的作用的研究进展。
Zotero 插件